Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Gains from Sales and Divestitures (2020 - 2025)

Revolution Medicines (RVMD) has 6 years of Gains from Sales and Divestitures data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Gains from Sales and Divestitures rose 33.43% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, up 33.43%, while the annual FY2025 figure was $1.3 million, 33.43% up from the prior year.
  • Gains from Sales and Divestitures reached $1.3 million in Q4 2025 per RVMD's latest filing, up from $978467.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $1.3 million in Q4 2025 and bottomed at $1798.0 in Q1 2021.
  • Average Gains from Sales and Divestitures over 5 years is $386627.2, with a median of $265839.5 recorded in 2023.
  • Peak YoY movement for Gains from Sales and Divestitures: skyrocketed 4540.69% in 2021, then skyrocketed 33.43% in 2025.
  • A 5-year view of Gains from Sales and Divestitures shows it stood at $78010.0 in 2021, then skyrocketed by 257.45% to $278848.0 in 2022, then surged by 106.91% to $576974.0 in 2023, then soared by 75.27% to $1.0 million in 2024, then skyrocketed by 33.43% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Sales and Divestitures were $1.3 million in Q4 2025, $978467.0 in Q3 2025, and $633511.0 in Q2 2025.